Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells
- PMID: 14633716
Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells
Abstract
The effects of geldanamycin (GA), 17-(3-aminopropylamino)-17-demethoxygeldanamycin (AP-GA), and N-(2-hydroxypropyl)methacrylamide copolymer-AP-GA conjugate [P(AP-GA)] on A2780 human ovarian carcinoma cells at an equitoxic dose (2x IC(50)) were compared by the gene expression array analysis. All treatments resulted in similar gene expression profiles up to 12 h (e.g., down-regulation of CDK4 and up-regulation of APAF-1), although P(AP-GA)-treated cells showed delayed gene expression because of time-dependent internalization of the conjugate and intracellular drug release from P(AP-GA). However, AP-GA-treated cells showed elevated expression of HSP70 and HSP27 after 6 h compared with that observed by GA and P(AP-GA) treatments. Depletion of C-Raf, an HSP90 client protein, was observed in all treatments up to 12 h. Confocal microscopy using mesochlorin e(6) as a model drug revealed that drug release caused by the lysosomal cleavage of glycylphenylalanylleucylglycine oligopeptide spacer, used as GA derivative copolymer attachment/release point, was moderately fast. These results suggested that AP-GA treatment may activate stress-response pathways, whereas P(AP-GA) treatment may suppress them and trigger signaling pathways essential to cell growth arrest and death by inducing an HSP90-active factor. Although GA and P(AP-GA) treatments induced a time-dependent increase in HSP70 and HSP27 protein expression (detected by Western blotting analysis), AP-GA treatment resulted in more rapid and more intense expression of both proteins. Our results suggest that conjugation of AP-GA to N-(2-hydroxypropyl)methacrylamide copolymer may be able to modulate the cell stress responses induced by AP-GA because of differences in its internalization mechanism, subcellular localization, and intracellular concentration gradients.
Similar articles
-
Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells.IUBMB Life. 1999 Oct;48(4):429-33. doi: 10.1080/713803536. IUBMB Life. 1999. PMID: 10632574
-
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7023-32. doi: 10.1158/1078-0432.CCR-05-0518. Clin Cancer Res. 2005. PMID: 16203796
-
Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro.Biochem Biophys Res Commun. 2004 Aug 27;321(3):665-9. doi: 10.1016/j.bbrc.2004.07.021. Biochem Biophys Res Commun. 2004. PMID: 15358157
-
[Advances in antitumor activity of the hsp90 inhibitor geldanamycin].Yao Xue Xue Bao. 2001 Sep;36(9):716-20. Yao Xue Xue Bao. 2001. PMID: 12580116 Review. Chinese. No abstract available.
-
[The potential role of heat shock proteins in the treatment of ovarian cancer].Orv Hetil. 2011 Jan 16;152(3):92-5. doi: 10.1556/OH.2011.29024. Orv Hetil. 2011. Retraction in: Orv Hetil. 2011 Dec 25;152(52):2112. PMID: 21205608 Retracted. Review. Hungarian.
Cited by
-
Medicinal facilities to B16F10 melanoma cells for distant metastasis control with a supramolecular complex by DEAE-dextran-MMA copolymer/paclitaxel.Drug Deliv Transl Res. 2015 Feb;5(1):38-50. doi: 10.1007/s13346-014-0213-z. Drug Deliv Transl Res. 2015. PMID: 25787338
-
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).Int J Oncol. 2013 Feb;42(2):373-83. doi: 10.3892/ijo.2012.1754. Epub 2012 Dec 28. Int J Oncol. 2013. PMID: 23291656 Free PMC article. Review.
-
Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload.Pharm Res. 2017 Dec;34(12):2735-2748. doi: 10.1007/s11095-017-2249-5. Epub 2017 Sep 14. Pharm Res. 2017. PMID: 28913790
-
Polymer nanomedicines.Adv Drug Deliv Rev. 2020;156:40-64. doi: 10.1016/j.addr.2020.07.020. Epub 2020 Jul 28. Adv Drug Deliv Rev. 2020. PMID: 32735811 Free PMC article. Review.
-
HPMA copolymers: origins, early developments, present, and future.Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49. doi: 10.1016/j.addr.2009.10.004. Epub 2009 Nov 14. Adv Drug Deliv Rev. 2010. PMID: 19919846 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials
Miscellaneous